Methods and devices for detection of anticoagulants in plasma and whole blood

A microfluidic device, a technology for blood clots, applied in the field of assessing coagulation in blood samples, detecting anticoagulants or abnormal coagulation, and solving problems such as limited functional information

Pending Publication Date: 2020-05-01
MASSACHUSETTS INST OF TECH +1
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most DOAC assays that have been proposed are pharmacokinetic assays that measure the absolute concentration of the drug itself and thus provide limited functional information to support clinical decision making

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and devices for detection of anticoagulants in plasma and whole blood
  • Methods and devices for detection of anticoagulants in plasma and whole blood
  • Methods and devices for detection of anticoagulants in plasma and whole blood

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0148] Figures 1A to 1D is a schematic illustration of a microfluidic device layout according to some exemplary embodiments of the invention.

[0149] Figure 1A is a top view of a circular layout (which can also be any symmetrical polygon with a center point) of a microfluidic device 10 with one or more continuous microfluidic channels formed in a substrate 15 (eg, microchannels) 20, each channel is connected to an inlet (input port) 30 and an outlet (output port) 35. A portion of the channel (eg, the center of the channel) may have a unique shape (eg, clot formation / localization region 25 ) to achieve flow separation or perturbation, or stagnation of sample flow to promote clot formation. Depending on the particular assay used, there may be two or more of these microfluidic channels in the single device. This design may allow multiple samples to be evaluated simultaneously, eg three or more samples, eg up to 10 samples or more than 10 samples. Typically, each sample (or...

Embodiment 2

[0158] A general protocol for performing an assay according to one embodiment of the invention is as follows:

[0159] a) Add sample, agonist, + / - calcium, + / - clot detection reagent together

[0160] i. The final concentration of calcium is 0.2mM (This concentration is especially suitable for use with 3.2% buffered sodium citrate. If using additional anticoagulants, the concentration of calcium may be different from 0.2mM.)

[0161] ii. Blood clot detection reagents can include fluorescently labeled fibrinogen, magnets, beads (can be fluorescent or colored)

[0162] b) Loading into a microfluidic device

[0163] i. For an example of entering the load configuration and order, see e.g. Figures 1A to 1D , 2A and 2B

[0164] c) Temperature control

[0165] i. room temperature

[0166] ii. Can rise to 37°C (body temperature)

[0167] (The body temperature is usually 37°C, but the temperature of the assay run can be changed according to the actual temperature of the patient....

Embodiment 3

[0171] Figures 3A to 3C Blood clot detection using plasma and fluorescently labeled fibrinogen is shown with a microfluidic device 310 having four channels 320 and a clot formation / localization region 225 according to an exemplary embodiment. The microfluidic device is similar to Figure 2A and Figure 2B The device shown in , differs in that all clot formation regions 325 have the same shape. Each clot formation / localization region 325 contains protrusions for perturbing sample flow. In this example, as Figure 3A As shown in , the protrusions are usually triangular in shape. Two sides of the protrusion are straight and one side is concave. Each clot formation region 325 redirected the flow four times, including two 90 degree changes of direction.

[0172] In one example, the blood clot detection process may include the following procedural steps:

[0173] a) Plasma samples were premixed to contain: 6 μL plasma + 0.6 μL agonist (10% sample volume) + 0.6 μL calcium (st...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods and devices for evaluating coagulation are described, including methods and devices for detecting an anticoagulant agent or a coagulation abnormality. In various embodiments, the methods and devices of the invention measure the coagulation of a sample in response to a gradient of one or more coagulation factors. These responses can be evaluated to accurately profile the coagulation impairments of the sample, including the presence of anticoagulant medication. In various embodiments, the invention provides the point-of-care or bedside testing with a convenient, microfluidic device thatcan be used by the minimally trained personnel.

Description

[0001] related application [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 538,618, filed July 28, 2017, and U.S. Provisional Application No. 62 / 699,665, filed July 17, 2018, the entire contents of which are hereby incorporated by reference . [0003] governmental support [0004] This invention was made with Government support under Grant Nos. P41 EB002503, P30 ES002109, and P50GM021700 awarded by the National Institutes of Health. The government has certain rights in this invention. Background technique [0005] The coagulation system is a delicate balance between bleeding and thrombus formation. There are many disease states including cancer, autoimmune disease, infection, trauma, surgery, heart disease, and drugs that can cause disruption of this balance and lead to severe or even life-threatening bleeding or clotting events in the patient. Anticoagulants are usually prescribed for thrombotic disorders. Conventional anticoagulant dr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/86G01N33/49
CPCG01N33/4905G01N33/86A61K38/4846B01L3/502746B01L3/502761B01L2300/165B01L2400/0406B01L2400/088
Inventor 加利特·H·弗里德曼穆罕默德·托纳罗纳德·G·汤普金斯帕万·本达普迪
Owner MASSACHUSETTS INST OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap